Biotech RadarJobs updated

COMPANY

VaxCyte

HQ: San Carlos, CA source · vaxcyte.com ↗ · West Coast

Clinical Phase 3

43 open jobs · last seen Oct 23, 2026 · 13 sources

Keywords: vaccine infectious disease Pneumococcal Vaccines influenza PCV20 PCV21

Profile checked Oct 10, 2026

Since the raise (Feb 2, 2026): 43 of 43 open jobs were first seen after it.

43Open jobs$632.5MRaised (2 yrs)9Trials (company is sponsor)1NIH grants

Hiring

TitleLocation (from posting)Employer postedFirst seen
Director, Global Drug Substance Commercialization, PolysaccharideSan Carlos, California, United StatesOct 21, 2026Oct 22, 2026
Associate Director, Business Operations & Digital EnablementSan Carlos, California, United StatesOct 19, 2026Oct 20, 2026
Associate Director, Business Process Management & Operational ExcellenceSan Carlos, California, United StatesOct 14, 2026Oct 15, 2026
Manager Accounting , Inventory and OperationsSan Carlos, California, United StatesOct 14, 2026Oct 15, 2026
Senior AccountantSan Carlos, California, United StatesOct 14, 2026Oct 15, 2026

See all 43 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (43 open jobs at last check). source ↗
  2. Debt Debt: $500M (not counted as a raise), announced Oct 7, 2026. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 1: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults source ↗
  4. Trial start Phase 3: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination source ↗
  5. Raise Follow-on offering: $632.5M (total, as published), announced Feb 2, 2026. Source: company release on GlobeNewswire. source ↗
  6. Trial start Phase 3: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age source ↗
  7. Trial start Phase 3: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 source ↗
  8. Trial start Phase 2: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants source ↗
  9. Trial start Phase 1/Phase 2: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults source ↗
  10. Trial start Phase 2: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants source ↗
  11. Trial start Phase 2: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults source ↗
  12. Trial start Phase 1/Phase 2: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 43

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Director, Global Drug Substance Commercialization, PolysaccharideSan Carlos, California, United StatesOct 21, 2026Oct 22, 2026Not stated
Associate Director, Business Operations & Digital EnablementSan Carlos, California, United StatesOct 19, 2026Oct 20, 2026Not stated
Associate Director, Business Process Management & Operational ExcellenceSan Carlos, California, United StatesOct 14, 2026Oct 15, 2026Senior
Manager Accounting , Inventory and OperationsSan Carlos, California, United StatesOct 14, 2026Oct 15, 2026Senior
Senior AccountantSan Carlos, California, United StatesOct 14, 2026Oct 15, 2026Senior
Scientist II (Contract), Analytical DevelopmentSan Carlos, California, United StatesOct 12, 2026Oct 12, 2026Mid
Systems EngineerSan Carlos, California, United StatesOct 12, 2026Oct 12, 2026Mid
Senior Associate Scientist, ResearchSan Carlos, California, United StatesOct 12, 2026Oct 12, 2026Mid
Associate Scientist II, ResearchSan Carlos, California, United StatesOct 12, 2026Oct 12, 2026Mid
IT Operations EngineerSan Carlos, California, United StatesOct 9, 2026Oct 10, 2026Mid
Manager, Facilities EngineeringSan Carlos, California, United StatesOct 8, 2026Oct 9, 2026Mid
Scientist I, Drug Product Analytics (Laboratory Automation)San Carlos, California, United StatesOct 5, 2026Oct 9, 2026Entry
Senior Manager, Quality Control Operations, Global AnalyticsVisp, Valais, SwitzerlandOct 5, 2026Oct 9, 2026Senior
Staff Scientist, Immunoassay DevelopmentSan Carlos, California, United StatesOct 2, 2026Oct 9, 2026Senior
Associate Scientist II, Immunoassay DevelopmentSan Carlos, California, United StatesOct 1, 2026Oct 9, 2026Mid
Scientist II, Upstream Polysaccharide Process DevelopmentSan Carlos, California, United StatesSep 30, 2026Oct 9, 2026Mid
Senior Scientist, Analytical DevelopmentSan Carlos, California, United StatesSep 17, 2026Oct 9, 2026Senior
Senior Manager, Clinical Quality AssuranceSan Carlos, California, United StatesSep 15, 2026Oct 9, 2026Senior
Staff Bioprocess Engineer, MSAT, ProteinsVisp, Valais, SwitzerlandSep 11, 2026Oct 9, 2026Senior
Associate Director, Commercial Project ManagementSan Carlos, California, United StatesSep 11, 2026Oct 9, 2026Senior
Scientist II, Analytical Development (Contract)San Carlos, California, United StatesSep 8, 2026Oct 9, 2026Mid
Lab Compliance ManagerSan Carlos, California, United StatesAug 27, 2026Oct 9, 2026Senior
Staff Engineer, Process Development and ManufacturingSan Carlos, California, United StatesAug 19, 2026Oct 9, 2026Senior
Senior Manager, Immunoassay DevelopmentSan Carlos, California, United StatesAug 4, 2026Oct 9, 2026Senior
Director, Supply Chain, ERP TransformationSan Carlos, California, United StatesJul 23, 2026Oct 9, 2026Senior
Executive Director, Digital EnablementUS - RemoteJul 20, 2026Oct 9, 2026Executive
Associate Director, QC Global AnalyticsSan Carlos, California, United StatesJul 20, 2026Oct 9, 2026Senior
Senior Engineer, Device DevelopmentSan Carlos, California, United StatesJul 7, 2026Oct 9, 2026Senior
Senior Manager, Manufacturing Systems & Operations Readiness (Contractor)Visp, Valais, SwitzerlandJun 30, 2026Oct 9, 2026Senior
Scientist II, Upstream Development for Protein Development and ManufacturingSan Carlos, California, United StatesJun 29, 2026Oct 9, 2026Mid
Senior Manager, Quality AssuranceVisp, Valais, SwitzerlandJun 22, 2026Oct 9, 2026Senior
Scientist II, Conjugation DevelopmentSan Carlos, California, United StatesJun 18, 2026Oct 9, 2026Mid
Engineer II, Conjugation Development and ManufacturingSan Carlos, California, United StatesJun 12, 2026Oct 9, 2026Mid
Senior Scientist, Immunoassay Development, Antibody Critical Reagents & Reference MaterialsSan Carlos, California, United StatesJun 10, 2026Oct 9, 2026Senior
Vice President, U.S. Market Access & PricingSan Carlos, California, United StatesJun 4, 2026Oct 9, 2026Executive
Senior Associate Scientist (Contract), Formulation DevelopmentSan Carlos, California, United StatesMay 13, 2026Oct 9, 2026Mid
Senior Azure Cloud EngineerSan Carlos, California, United StatesMar 13, 2026Oct 9, 2026Senior
Associate Director, SEC Reporting & Technical AccountingSan Carlos, California, United StatesFeb 26, 2026Oct 9, 2026Senior
Director, Immunoassay DevelopmentSan Carlos, California, United StatesFeb 25, 2026Oct 9, 2026Senior
AI Implementation Consultant – LegalSan Carlos, California, United StatesDec 2, 2025Oct 9, 2026Mid
Stability ManagerSan Carlos, California, United StatesSep 2, 2025Oct 9, 2026Senior
Associate Director, Data and Knowledge ManagementSan Carlos, California, United StatesJul 1, 2025Oct 9, 2026Senior
Don't see a role you're looking for? Please submit your resume for future considerationSan Carlos, California, United StatesMar 31, 2025Oct 9, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $632.5M · Debt: $500.0M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT07365826A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgePhase 3Active, not recruitingJan 12, 20262027-03 (estimated)
NCT07425392Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationPhase 3Active, not recruitingFeb 9, 20262027-03 (estimated)
NCT07616934A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young AdultsPhase 1RecruitingJun 1, 20262027-12 (estimated)
NCT06720038A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsPhase 2Active, not recruitingNov 25, 20242027-12 (estimated)
NCT07284654Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49Phase 3Active, not recruitingDec 1, 20252027-01 (estimated)
NCT05844423Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsPhase 2CompletedMar 29, 2023Aug 25, 2025 (actual)
NCT06151288Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in AdultsPhase 1/Phase 2CompletedNov 8, 2023Jul 17, 2024 (actual)
NCT05297578Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsPhase 2CompletedJun 15, 2022Feb 15, 2023 (actual)
NCT05266456Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in AdultsPhase 1/Phase 2CompletedFeb 22, 2022Jan 10, 2023 (actual)

NIH awards 1

Annual award amounts. Total $196K.

Feedback